



**NEVADA  
HEALTH  
RESPONSE**

**FOR IMMEDIATE RELEASE**

April 26, 2021

Meghin Delaney

Communications Director

CONTACT: [pressroom@nvhealthresponse.nv.gov](mailto:pressroom@nvhealthresponse.nv.gov)

**COVID-19 Press Bulletin for 4-26-2021**

Carson City, NV — Today, Caleb Cage, Nevada COVID-19 Response Director and Karissa Loper, Bureau Chief for the Bureau of Child, Family, and Community Wellness provided updates on Nevada's ongoing COVID-19 response and vaccination efforts in Nevada during a call with members of the media.

This bulletin provides facts, figures, and informational items from the call. As a reminder, data is provided in a dashboard on the home page of the [Nevada Health Response](https://www.nvhealthresponse.nv.gov) website.

**SUMMARY:**

- As of today, Nevada has logged 313,680 cases, with the 14-day rolling average of daily cases being 271.
- Nevada has now completed a total of 3,155,257 molecular tests since the beginning of COVID-19.
- The test positivity rate over the last 14 days is 5.7%.
- Today, the Nevada Hospital Association is reporting there are currently 324 COVID-19 hospitalizations (270 confirmed; 54 suspected).

- As of April 25, 1,805,244 COVID-19 vaccine doses (By Resident County) were administered and reported to Nevada WebIZ.
- 44.3% of the population 16 and older has initiated vaccination and 30.5% of the population 16 and older has completed vaccination.
- On Friday, the CDC's Advisory Committee on Immunization Practices, or ACIP, met to further review the Janssen vaccine and the rare but serious reactions reported.
- The ACIP recommended ending the pause and the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) announced they would lift the pause following this recommendation.
- Following this announcement, the Western States Scientific Safety Review Workgroup also recommended resuming use of the Janssen vaccine.
- The Janssen vaccine has been found to be safe and effective. The reaction to the vaccine is very rare and the benefits outweigh the risk.
- The Nevada State Immunization Program notified enrolled providers of the updated recommendation and the Janssen vaccine is now being used again in Nevada.
- When individuals receive the Janssen vaccine they will also receive additional information about the possible risks.
- People who have received the Janssen vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact a health care provider.

- Health care providers are required to report adverse events to the federal Vaccine Adverse Event Reporting System.
- The Mobile Vaccination Unit or MVU on the Northern route was in Duck Valley Reservation in Owyhee yesterday and will be in Wells tomorrow from 11 a.m. to 7 p.m.
- On the Southern route the MVU will be at the Paiute Shoshone Tribe in Fallon tomorrow administering vaccines from 12 p.m. (noon) to 8 p.m.
- A reminder, these MVU events are first come, first serve events and the MVUs are now stocked with both the Pfizer and Janssen vaccines. Pfizer is available to any Nevadan 16 and older and the Janssen will be available to those 18 and older.
- As always, Nevadans are encouraged to check out [NVCOVIDFighter.org](https://www.nvcoVIDfighter.org) or call 1-800-401-0946 for the latest information on appointment availability in their county.

###